Switch Contrast

Discovery of a new approach for treating fibrosis

19.11.2026 Label 2026 Label Research Label Prof. Dr. Sabine Eming Label Prof. Dr. Björn Schumacher

Working model for Interleukin 4-receptor-α blockade in localized scleroderma. Blocking IL-4/IL-13 signaling attenuates type 1 and type 2 immune responses as well as gene signatures associated with a risk for the development of fibrosis.
Interleukin-4-receptor-α

A recent multicentre study led by researchers in Cologne has demonstrated the efficacy of interleukin-4 receptor ∝ blockade in the treatment of localized scleroderma / publication in the ‘Annals of the Rheumatic Diseases’

 

In an Investigator Initiated Trial, researchers have shown that inhibiting the cytokines IL-4 and IL-13 can prevent fibrosis in the skin disease localized scleroderma. These findings could pave the way for the prevention and treatment of other fibrotic conditions. The study “Interleukin 4 receptor-∝ blockade in localised scleroderma: a phase II proof-of-concept study” was published in the journal Annals of the Rheumatic Diseases.

Fibrotic diseases are common and pose a major challenge for the medical profession. They are also extremely burdensome for those affected. Fibrosis is a pathological condition of the connective tissue, which is characterized by progressive hardening and loss of tissue function. The risk of developing tissue fibrosis increases with age, and in principle any organ can be affected. At present, only a few medications are approved for fibrotic conditions.

Preclinical studies have already shown that the cytokines IL-4 and IL-13 play a crucial role in the development of fibrosis. The interdisciplinary team, led by Professor Dr Sabine Eming, Professor of Dermatology, Senior Researcher at the University of Cologne’s CECAD Cluster of Excellence on Aging Research and Director of the Center for Molecular Medicine Cologne (CMMC), has now carried out a proof-of-concept study in humans. This type of study involves an early assessment as to whether an active substance works as intended and delivers initial benefits, so that a decision can be made regarding its further development. The results demonstrated that IL-4/IL-13 signalling plays a key role in the inflammatory process leading to fibrosis. Targeted inhibition of this signalling pathway improved the course of the disease in the participants. 

Eming and her team investigated the selective inhibition of IL-4/IL-13 signalling in the fibrotic skin condition known as localized scleroderma in a randomized, placebo-controlled clinical trial involving 45 participants. Over a period of six months, the study investigated the effect of a blockade on the course of the disease, on inflammation, and on gene expression. The drug used for this purpose was dupilumab, which inhibits IL-4/IL-13 signalling and is already used as an anti-inflammatory agent in conditions such as neurodermatitis and asthma. Even within this short period, there was a marked clinical improvement over the placebo, a significant reduction in local inflammation, and suppression of fibrosis-associated genes.

“The study findings are very promising for the therapeutic prevention of other fibrotic diseases,” explains Sabine Eming. “Our findings support the need for follow-up studies involving a larger number of patients and a longer duration of treatment in order to validate the efficacy and safety of long-term treatment with dupilumab in patients with localized scleroderma.”

For content-related enquiries:

Professor Dr Sabine Eming

sabine.eming[at]uni-koeln.de

Press and communications team:

Ulrike Doose 

CECAD PR & Communication Manager

+49 221 478 15806

u.doose[at]uni-koeln.de 

Publication:

https://www.sciencedirect.com/science/article/pii/S0003496726006059?via%3Dihub

DOI: 10.1016/j.ard.2026.09.022

Telephone BookCECAD on BlueskyCECAD on FacebookCECAD on YoutubeCECAD on LinkedIn